The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases
Clinical trial NCT05877001 · UNKNOWN
Trial details
- NCT number
- NCT05877001
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-30
- Primary completion
- 2024-07-30
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.